News
Nextera is very pleased to announce that the Norwegian Research Council (NRC) has awarded a grant through the Innovation Project for the Industrial Sector (IPN) to support our continued development of TCR-Like antibodies as novel therapy in autoimmune diseases such as...
Nextera present on the premier annual protein engineering venue in Europe - PEGS Europe. As part of the Display of Biologics scientific advisory board, our CEO/CSO Geir Åge Løset will be chair for the morning session "ACCELERATING AND IMPROVING THERAPEUTIC PROTEIN...
Nextera AS (Oslo, Norway) announces a collaboration with Karolinska Institutet (Stockholm, Sweden) on joint development of next generation targeted tolerizing immunotherapy for the treatment of patients with Rheumatoid Arthritis (RA). The collaboration will support a...
The Nextera team is excited about returning to the PEGS scene – the annual major Protein & Antibody Engineering Summit in Europe 5 – 7 November in Barcelona! Antibody engineering and development towards novel therapy have never had greater momentum...
The Festival of Biologics event, renowned for bringing together industry leaders and innovators, will take place from October 15-17, 2024. Nextera will be showcasing its latest research and PoC on targeting peptide HLA in oncology, utilizing our proprietary NextCore...
Nextera is attending the BIO International Convention in San Diego June 3 – 6, 2024! Please get in touch if you would like to meet us and learn more about our approach in engineered TCR-Like antibody guiding towards pHLA targets with transformational...
Harnessing the power of T cell immunity in the form of biologics holds tremendous potential in cancer immunotherapy. A new area of engineered guiding to pHLA with precision specificity and sensitivity beyond that of the natural T cell in the form of T cell engagers...
Nextera is attending the BIO Partnering @JPM Week 2024 in San Francisco, January 8 – 12, 2024. Please get in touch if you would like to meet us and learn more about our approach to next generation targeted immunotherapy!
CAR-based adoptive cell therapy (ACT) has shown a remarkable ability to treat and occasionally cure cancer by evoking or grafting an anti-cancer immune response into patients with hematological malignancies but has yet to show similar efficacy in solid tumors. In...
CEO/CSO Geir Åge Løset and Head of Business Development Francis Yuan will attend the BIO Europe 2023 in Munich, Germany, November 6 – 8. We are interested in discussing partnerships, collaborations, and asset out-licensing - please get in touch if you would like...